Get Your ANDA Approved: The Generic Manufacturer’s Complete Checklist for Timely FDA Approval
A practical guide for regulatory affairs teams, IP counsel, and C-suite decision-makers The Stakes of the First Submission Every year, […]
Read the Orange Book, Then Ignore It: How Smart Supply Chains Use Patent Intelligence
The Gap Between Patent Data and Supply Chain Decisions Every procurement director at a hospital system, every formulary manager at
Read the Orange Book, Then Ignore It: How Smart Supply Chains Use Patent Intelligence Read Post »
Pick the Right Pathway: How 505(b)(2) Beats the Branded Generic Every Time — Unless It Doesn’t
The Decision That Determines Your Revenue Ceiling Somewhere between completing a Phase II study and walking into an FDA pre-NDA
The Generic Price Drop: Exact Benchmarks for What Happens to Drug Costs in the First Year
The Moment the Monopoly Ends On November 30, 2011, Lipitor lost its U.S. patent protection. Within 90 days, the price
The $200 Billion Signal Most BizDev Teams Miss Every Year: Why drug patent loss-of-exclusivity alerts are the competitive intelligence tool biopharma business development can no longer afford to ignore
The Problem With Waiting Every year, branded pharmaceutical companies watch billions in revenue walk out the door, and generic manufacturers
How Long Do Drug Patents Last? The Complete Global Guide
Drug companies don’t make drugs. They make time. Patents are the mechanism by which a pharmaceutical firm converts a decade
How Long Do Drug Patents Last? The Complete Global Guide Read Post »
Find the Cracks First: How to Identify Weak Drug Patents Before Paragraph IV Filers Do
The $3.5 Billion Miscalculation In 2011, Warner Chilcott and Allergan settled a Paragraph IV lawsuit over the branded proton pump
Find the Cracks First: How to Identify Weak Drug Patents Before Paragraph IV Filers Do Read Post »
Win the Deal Before the Patent Drops: How regulatory and legal service firms can build a repeatable, high-margin revenue stream by delivering patent landscape intelligence in the five years before clients’ blockbusters go generic
The Five-Year Window Is Not Generous When a branded drug loses patent exclusivity, its manufacturer does not get to negotiate
Abandoned Patents Are Your Cheapest R&D Lab
How generic and 505(b)(2) developers mine expired and lapsed pharmaceutical patents for low-cost market entry The drug development world has
Abandoned Patents Are Your Cheapest R&D Lab Read Post »
